| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5325 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 755 | 2021 |
| Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK KB Pouwels, E Pritchard, PC Matthews, N Stoesser, DW Eyre, KD Vihta, ... Nature medicine 27 (12), 2127-2135, 2021 | 618 | 2021 |
| Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey KB Pouwels, T House, E Pritchard, JV Robotham, PJ Birrell, A Gelman, ... The Lancet Public Health 6 (1), e30-e38, 2021 | 180 | 2021 |
| Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over time AS Walker, E Pritchard, T House, JV Robotham, PJ Birrell, I Bell, JI Bell, ... Elife 10, e64683, 2021 | 97 | 2021 |
| Tracking the emergence of SARS-CoV-2 alpha variant in the United Kingdom AS Walker, KD Vihta, O Gethings, E Pritchard, J Jones, T House, I Bell, ... New England Journal of Medicine 385 (27), 2582-2585, 2021 | 71 | 2021 |
| Increased infections, but not viral burden, with a new SARS-CoV-2 variant AS Walker, KD Vihta, O Gethings, E Pritchard, J Jones, T House, I Bell, ... MedRxiv, 2021.01. 13.21249721, 2021 | 66 | 2021 |
| Prognostic and therapeutic relevance of c‐FLIP in acute myeloid leukaemia D McLornan, J Hay, K McLaughlin, C Holohan, AK Burnett, RK Hills, ... British journal of haematology 160 (2), 188-198, 2013 | 46 | 2013 |
| Symptoms and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity in the general population in the United Kingdom KD Vihta, KB Pouwels, TEA Peto, E Pritchard, DW Eyre, T House, ... Clinical Infectious Diseases 75 (1), e329-e337, 2022 | 32 | 2022 |
| SARS-CoV-2 positivity in asymptomatic-screened dental patients DI Conway, S Culshaw, M Edwards, C Clark, C Watling, C Robertson, ... Journal of dental research 100 (6), 583-590, 2021 | 29 | 2021 |
| Viral load in community SARS-CoV-2 cases varies widely and temporally AS Walker, E Pritchard, T House, JV Robotham, PJ Birrell, I Bell, JI Bell, ... MedRxiv, 2020.10. 25.20219048, 2020 | 28 | 2020 |
| AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B-cell receptor-mediated survival E Cosimo, A Tarafdar, MW Moles, AK Holroyd, N Malik, MA Catherwood, ... Clinical Cancer Research 25 (5), 1574-1587, 2019 | 26 | 2019 |
| The RUNX Genes as Conditional Oncogenes: Insights from Retroviral Targeting and Mouse Models JC Neil, K Gilroy, G Borland, J Hay, A Terry, A Kilbey RUNX Proteins in Development and Cancer, 247-264, 2017 | 15 | 2017 |
| Disrupting MLV integrase: BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model L Loyola, V Achuthan, K Gilroy, G Borland, A Kilbey, N Mackay, M Bell, ... PLoS pathogens 15 (12), e1008154, 2019 | 13 | 2019 |
| RUNX‐mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins G Anderson, N Mackay, K Gilroy, J Hay, G Borland, A McDonald, M Bell, ... Journal of Cellular Biochemistry 119 (3), 2750-2762, 2018 | 11 | 2018 |
| Addiction to RUNX1 is partially attenuated by loss of p53 in the Eμ-Myc lymphoma model G Borland, A Kilbey, J Hay, K Gilroy, A Terry, N Mackay, M Bell, ... Oncotarget 7 (17), 22973, 2016 | 11 | 2016 |
| mTORC1 activity is essential for erythropoiesis and B cell lineage commitment N Malik, KM Dunn, J Cassels, J Hay, C Estell, OJ Sansom, AM Michie Scientific Reports 9 (1), 16917, 2019 | 8 | 2019 |
| Collaboration of MYC and RUNX2 in lymphoma simulates T‐cell receptor signaling and attenuates p53 pathway activity J Hay, K Gilroy, C Huser, A Kilbey, A Mcdonald, A MacCallum, A Holroyd, ... Journal of Cellular Biochemistry 120 (10), 18332-18345, 2019 | 7 | 2019 |
| Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy JF Hay, K Lappin, F Liberante, LM Kettyle, KB Matchett, A Thompson, ... Oncotarget 8 (40), 67891, 2017 | 5 | 2017 |
| Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells H Donnelly, E Ross, Y Xiao, R Hermantara, A Taqi, ... bioRxiv, 2022.07. 28.501818, 2022 | 4 | 2022 |
Fabio LiberanteELIXIR, Cambridge, UKVerified email at ebi.ac.uk
